<DOC>
	<DOC>NCT01783730</DOC>
	<brief_summary>This study was conducted to examine the safety profile and the effectiveness in daily clinical practice of adalimumab in rheumatoid arthritis participants showing rapid progression of structural damage of the joints, who had no prior history of treatment with disease-modifying anti-rheumatic drugs or biological agents.</brief_summary>
	<brief_title>Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents</brief_title>
	<detailed_description>This was a multicenter, prospective, observational study of adalimumab. Each participant enrolled when initiating adalimumab treatment and was to be followed up for 24 weeks or until discontinuation of the drug.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. High disease activity, with poor prognostic factors (e.g., rheumatoid factor [RF]positive, anticyclic citrullinated peptide [CCP] antibodypositive, or bone erosion) 2. Combination of adalimumab and methotrexate will be started 3. No prior history of treatment with diseasemodifying antirheumatic drugs 4. No prior history of treatment with biological agents 5. Adalimumab dosed according to the registered product label 6. Signed informed consent There were no specific exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>